The conference, spearheaded by the Arizona BioIndustry Association (AZBio), is presented by the National Venture Capital Association and leading life science associations of the Rocky Mountain Southwest Region, including the CBSA. This conference is showcasing 34 of the region’s top life science companies to interested investors including business development professionals from large pharmaceutical, biotechnology, medical device and diagnostic companies.
“The Rocky Mountain and Southwest Regions have become increasingly recognized for their growth in the bioscience and heath care innovations. The White Hat Life Science Investor Conference will act as another opportunity to highlight the work being done in Colorado and the surrounding region while at the same time bringing new potential partners and investors into our community,” Giles said.
Colorado bioscience companies selected to present in the 2014 White Hat Investor Conference:
* EndoShape, Inc., Boulder – EndoShape’s mission is to commercialize novel medical devices based on its proprietary polymer technology. EndoShape is focused on the coil embolization and occlusion market. EndoShape is currently commercializing the Medusa™ Vascular Plug which is FDA 510(k) cleared for sale in the United States. Visit, http://www.endoshape.com.
* Fluonic, Inc., Boulder - Fluonic is a privately held medical device company dedicated to making infusion drug delivery safer for patients through the development of a new generation of infusion devices and information systems, driven by a breakthrough MEMS flow sensor technology. Fluonic infusion products improve patients’ safety and compliance while improving medical staff productivity and reducing costs, which will set a new standard of care for the industry. Visit, http://fluonic.com.
* ValveXchange, Inc. – Greenwood Village – ValveXchange (VXi) is dedicated to improving the lives of patients requiring heart valve replacements. VXi is developing a two-piece bioprosthetic tissue valve system that resolves the long standing compromises between conventional mechanical and tissue-based prosthetic valves. Unlike today’s transcatheter valves, the VXi technology is Without Compromise. The VXi exchangeable valve system is being designed to offer leaflet exchange, as well as the original implant, without open-heart surgery and without the safety and longevity compromises of transcatheter approaches. Visit: http://www.valvexchange.com.
For more information and a complete listing of presenting companies, visit the conference website at http://www.azbio.org/white-hat-investors-2014.
Link to the related PitchEngine Social Media Release